Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects

Nat Clin Pract Oncol. 2008 Nov;5(11):E1. doi: 10.1038/ncponc1275.
No abstract available

Publication types

  • Kommentar
  • Review

MeSH terms

  • Anthracyclines / administration & dosage
  • Anthracyclines / adverse effects*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / radiotherapy
  • Cardiovascular Diseases / chemically induced*
  • Cardiovascular Diseases / prevention & control*
  • Chemotherapy, Adjuvant / adverse effects
  • Evidence-Based Medicine
  • Female
  • Heart Diseases / chemically induced
  • Humans
  • Neoadjuvant Therapy / adverse effects
  • Neoadjuvant Therapy / methods
  • Risk Factors
  • Trastuzumab

Substances

  • Anthracyclines
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Trastuzumab